Cephalon has filed another lawsuit to protect its chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma treatment Treanda (bendamustine hydrochloride), this time against Canadian pharmaceutical company Uman Pharma.
Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).
The US Court of Appeals for the Federal Circuit has thrown out a lower court ruling that found Natco Pharma infringed a patent covering Roche’s flu drug Tamiflu (oseltamivir phosphate).
Depomed, a California-based pharmaceutical company, has settled litigation with two of three companies that sought to launch generic versions of its Gralise (gabapentin) product before patents covering it expire.
A group of generic drug manufacturers has asked the US Supreme Court to allow a ruling that grants them permission to market a version of Teva’s multiple sclerosis drug Copaxone (glatiramer acetate).
The UK High Court has invalidated two patents covering Roche’s breast cancer drug Herceptin (trastuzumab) after a challenge by generic drug maker Hospira.
OxyContin (oxycodone hydrochloride) maker Purdue Pharma has filed suit against Teva to stop the generic drug maker trying to litigate claims to a patent for which it had filed a Paragraph III certification.
Teva has filed an application with the US Supreme Court to stay a ruling by the US Court of Appeals for the Federal Circuit that allowed generic drug makers to enter the market before the expiry of Teva’s patents covering its $4.3 billion-a-year multiple sclerosis drug Copaxone.
Mumbai-based Sun Pharmaceutical Industries is buying Indian rival Ranbaxy Laboratories in a merger worth $3.2 billion, the companies have confirmed.
Generic drug maker Prasco Laboratories has agreed to market and distribute an authorised generic version of Eli Lilly’s Evista (raloxifene hydrochloride) in the US.